Abstract
Central sleep apnea (CSA) describes a group of conditions in which cessations in air flow occur without respiratory effort. In contrast, obstructive sleep apnea patients have ongoing respiratory effort during respiratory events. However, considerable overlap exists in the pathogenesis and clinical presentation of obstructive sleep apnea and CSA. A good working knowledge of the mechanisms underlying CSA is important for optimal clinical care. In general, CSA can be classified into those with excessive drive (eg, Cheyne-Stokes breathing) versus those with inadequate drive (eg, sleep hypoventilation syndrome). One critical factor contributing to the cessation of air flow during sleep is the concept of the apnea threshold, such that a PaCO2 value below a certain level will lead to cessations in breathing. PaCO2 can fall below the chemical apnea threshold when drive is excessive (eg, robust chemosensitivity) or when hyperventilation is occurring (eg, following arousal). Another important factor is the loss of the so-called wakefulness drive to breathe, such that some rise in PaCO2 is likely to occur at the onset of sleep. A variety of factors contribute to this rise, including upper-airway collapse and diminished chemosensitivity (particularly during rapid-eye-movement sleep). In patients with low central drive, this further loss of drive at sleep onset can lead to marked hypercapnia in some cases. The treatment of CSA is also reviewed in some detail, including a role for positive airway pressure (eg, bi-level positive airway pressure in hypoventilation patients) and optimization of medical therapy (eg, in Cheyne-Stokes breathing). A paucity of research exists in this area, emphasizing the opportunities for young investigators who are interested in this field.
- central sleep apnea
- CSA
- obstructive sleep apnea
- OSA
- lung
- Cheyne-Stokes breathing
- sleep hypoventilation syndrome
- sleep
- continuous positive airway pressure
- CPAP
Footnotes
- Correspondence: Atul Malhotra MD, Division of Sleep, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston MA 02115. E-mail: amalhotra1{at}partners.org.
Dr Malhotra presented a version of this paper at the 45th Respiratory Care Journal Conference, “Sleep Disorders: Diagnosis and Treatment” held December 10-12, 2009, in San Antonio, Texas.
Dr Malhotra has disclosed relationships with Philips, Pfizer, Merck, Apnex, Itamar, Sepracor, Cephalon, Sleep Group Solutions, Sleep HealthCenters, Medtronic, and Ethicon. Dr Owens has disclosed no conflicts of interest.
- Copyright © 2010 by Daedalus Enterprises Inc.